Comparing Uni- and Bi-lateral TBS in Major Depression

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS) is a very promising new treatment for major depression that allows a 15-fold reduction in duration of daily sessions. However, no large scale naturalistic study has assessed the superiority of bilateral TBS in comparison with unilateral left TBS. In fact, no TBS study thus far has included both unipolar and bipolar depression, or other psychiatric comorbidities such as anxiety. Maintenance has yet to be studied with TBS, along with an effective maintenance protocol to prevent relapse. Our study aims to explore and address these gaps.

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily session delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm which reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. However, it remains to be determined if applying TBS to both sides of the frontal cortex (i.e. bilateral TBS) is more efficient than delivering it to only one side (i.e. unilateral TBS). In addition, it is difficult to predict treatment response as there is a lack of tools to identify potential responders early on in the treatment phase. Finally, the effects of rTMS are known to last up to 12 months after the treatment. To avoid relapse, a maintenance phase is typically introduced after treatment in which treatment sessions are delivered at a gradually decreasing rate. This study proposes to bridge these gaps by conducting a randomized double-blinded naturalistic superiority trial in which the efficacy of bilateral and unilateral TBS will be compared in individuals with a diagnosis of major depressive episodes. Neurobiological markers of response will be assessed at different time points. In people that respond to treatment, a 6-month maintenance phase will be conducted using a flexible schedule. The study has four primary aims: To compare the efficacy of bilateral and unilateral TBS on symptoms of depression, as well as rates of remission and response To investigate how unilateral and bilateral TBS modulates brain activity in the dorsolateral prefrontal cortex (DLPFC) using interleaved TMS-EEG To investigate neural predictors of the clinical response to TBS. To compare the efficacy of a flexible schedule of maintenance on a period of 6 months on symptoms of depression and rate of relapse. TREATMENT PHASE TBS treatment will be administered 5 days/week (Monday to Friday) over a first phase of 4 weeks (20 sessions). If remission is achieved (Hamilton Rating Scale for Depression-17 scorescore ≤ 8), treatment will cease and the patient will move on to the maintenance phase. Non-remitters will receive a second phase of treatment, consisting of an additional 2 weeks (10 sessions, for a total of 30). After 6 weeks, all responders may move on to the maintenance phase. MAINTENANCE PHASE The maintenance phase will be of 6 months duration from the end of the randomized treatment. For each TBS condition, responders will be assigned to a flexible maintenance protocol based on symptom emergence. In the flexible protocol, participants will receive a fixed 2x/week schedule for the month 1. For month 2 and 3, a brief weekly assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions in the week. For month 4 and 5, a bimonthly assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions over the two weeks. For month 6, one brief assessment (Hamilton Rating Scale for Depression-17 score) will be conducted in which it will be determined if they will receive 0, 1 or 2 sessions in the month.

Both participants and research team members conducting the interviews and the TBS treatment will be blinded to the TBS treatment condition. In the unilateral arm, the right-sided stimulation will be applied with the placebo side of the coil. In the bilateral arm, the right-sided stimulation will be applied with the active side of the coil. As such, all participants will receive a total of 4 minutes of daily TBS. The master randomization list was created by a scientist of the research centre that is not involved in the research project. The patient's study ID code is entered into the device and a software-controlled switch then automatically selects the active or the sham coil for stimulation. The electronic positioning sensor built in the coil for monitoring the coil orientation checks against the entered patient's study ID and will enable the device and start the treatment procedure only if the coil orientation is matching the patient's study ID value.

Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Realistic sham continuous TBS (cTBS-sham) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).

Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC and continuous TBS (cTBS) will be applied to the right DLPFC. Participants will receive daily sessions (Mon-Fri) for 4 to 6 weeks (stop at 4 weeks if remission is achieved).

The flexible maintenance protocol will be based on symptom emergence. Participants will receive a fixed TBS (2x/week) schedule for the first month. For the following months (2-6), they will come in for an assessment (HRSD-17) to determine how many TBS sessions (0, 1, or 2) they receive on a flexible basis.

Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean Hamilton Rating Scale for Depression-17 score. The minimum value is 0 and the maximum value is 53. A higher score indicates a negative outcome.

Remission will be defined as a Hamilton Rating Scale for Depression-17 score ≤ 8 The minimum value is 0 and the maximum value is 53. A higher score indicates a negative outcome.

Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean Hamilton Rating Scale for Depression-17 score. The minimum value is 0 and the maximum value is 53. A higher score indicates a negative outcome

Remission will be defined as a Hamilton Rating Scale for Depression-17 score ≤ 8 The minimum value is 0 and the maximum value is 53. A higher score indicates a negative outcome.

Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean the Quick Inventory of Depression Symptomology-Self Report score. The minimum value is 0 and the maximum value is 48. A higher score indicates a negative outcome.

Remission will be defined as a Quick Inventory of Depression Symptomology-Self Report score ≤ 6. The minimum value is 0 and the maximum value is 48. A higher score indicates a negative outcome

Response to treatment will be defined as a > 50% reduction in pre-treatment symptoms severity as measured by the mean the Quick Inventory of Depression Symptomology-Self Report score. The minimum value is 0 and the maximum value is 48. A higher score indicates a negative outcome.

Remission will be defined as a Quick Inventory of Depression Symptomology-Self Report score ≤ 6. The minimum value is 0 and the maximum value is 48. A higher score indicates a negative outcome.

Investigate if baseline levels of GABA/Glutamate in the anterior cingulate cortex (ACC) and baseline levels of resting state connectivity between the left dorsolateral prefrontal. cortex (DLPFC) and ACC are linked to therapeutic response, using resting state functional magnetic resonance imaging (fMRI).

Inclusion Criteria: voluntary and competent to consent to study, female or male aged 18 years old or older, can speak and read English and/or French primary and/or predominant diagnosis of major depressive episode without psychotic features (confirmed by a Mini-International Neuropsychiatric Interview), depressive symptoms have not improved after ≥ 1 but ≤ 7 adequate dose of antidepressant trial in the current depressive episode, moderate symptoms in the current depressive episode as indexed by a score of at least 15 at the 17-item Hamilton Rating Scale for Depression (HRSD-17), have been referred to rTMS treatment by their treating physician, and took a free and informed decision to follow this treatment, are able to adhere to treatment schedule, have received a stable medication (including prescribed cannabis) or psychotherapy regiment for at least four weeks prior to entering the trial, have an education-adjusted score of ≥ 24 at the Mini-Mental State Evaluation (MMSE) if are aged ≥ 65. Exclusion Criteria: current or past (< 3 months) substance (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria current use of illegal substances or recreational cannabis have a concomitant major unstable medical or neurologic illness (e.g. uncontrolled diabetes or renal dysfunction), significant laboratory test abnormalities (e.g. thyroid dysfunctions), acute suicidality or threat to life from self-neglect, are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment, have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker), unwilling to maintain current antidepressant regiment, are taking more than 1 mg of lorazepam or equivalent, any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study, have failed a course of ECT within the current depressive episode due to the lower likelihood of response to rTMS.

All Individual Participant Data collected from this study (IPD) will be de-identified for all parties who have permission to access it. This de-identified data may be shared with other researchers at the Royal's Institute of Mental Health Research. De-identified may be shared with the public only upon request. Please note that all data that has the potential of revealing participants' identity will NOT be used to shared.

De-identified data may become available (upon request) when the study is completed and published (anticipated time frame: the year of 2023)

De-identified data will be accessible only through the permission of the lead research scientist. All requests must be made and accepted by her.